LAS VEGAS, NV–(Marketwired – August 28, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (“CV Sciences,” “our” or “we”), is pleased to announce today that they will be presenting at the MJAC2017 InvestorsHub International Cannabis Conference in Los Angeles, California on September 1-2, 2017 at the JW Marriott L.A. Live. CV Sciences will exhibit at Conference booth #308 showcasing its products, including samples, and will also have senior management available to speak with investors and attendees.
Event: MJAC2017 InvestorsHub International Cannabis Conference
Date: Saturday, September 2, 2017
Time: 10:10 AM (Pacific Time)
Location: Platinum F; JW Marriott L.A. Live
(Please double check conference agenda as times and location may be subject to change by conference provider)
Joseph Dowling, Chief Financial Officer of CV Sciences will present a company overview on both the pharmaceutical and consumer product divisions, including details about its lead drug candidate, CVSI-007, which utilizes synthetically-formulated cannabidiol for use in treatment of smokeless tobacco use and addiction.
CV Sciences’ President and CEO Michael Mona, Jr. commented, “We are excited to attend this industry-focused conference and look forward to continuing our leadership role in this sector. Cannabis is a booming industry and this conference provides investors an excellent forum to better understand the CV Sciences’ investment opportunity, generating from both our pharmaceutical and consumer product divisions.”
About CV Sciences, Inc.
CV Sciences, Inc. (CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.